Ivabradine Zentiva (Ivabradine)

Ivabradine works by selectively inhibiting the funny (If) current in the sino‑atrial node. This current drives spontaneous pacemaker activity; blocking it slows the depolarisation rate, resulting in a dose‑dependent reduction in heart rate while leaving myocardial contractility and conduction largely unchanged.

The dosage of Ivabradine Zentiva is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and tolerance. The prescriber determines the appropriate starting dose and any subsequent adjustments; patients should follow the specific instructions provided by their healthcare professional.

Safety data for ivabradine during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss risks with their physician, as the drug may be excreted in breast milk.

To order Ivabradine Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

The primary alternative for heart‑rate reduction in angina and heart‑failure is the beta‑blocker class. Beta‑blockers lower heart rate but also reduce myocardial contractility and can affect bronchial tone. Ivabradine specifically targets the If current, lowering heart rate without negative inotropic or bronchial effects, making it useful when beta‑blockers are contraindicated or not tolerated.

Ivabradine Zentiva tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Ivabradine Zentiva is taken orally as a tablet. It may be swallowed with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals, as food can affect absorption. The tablet should be swallowed whole with water and not chewed or crushed.

Serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare persistent visual disturbances that may affect retinal function. Patients should seek immediate medical attention if they experience dizziness, fainting, palpitations, new‑onset arrhythmias, or any sudden change in vision.

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), and in those taking strong CYP3A4 inhibitors. It should also be avoided in patients with known hypersensitivity to ivabradine or any of the tablet’s excipients.